The Benefit of Integrated Dual Disorders Service Utilization in the Survival of Patients in the Early Stages of Schizophrenia and Co-Occurring Substance use Disorders: a Long-Term Follow-Up Study

Yuri Gimelfarb1*, Alexander Ligay2, Julia Jerusalemsky3 and Mashit Ben Tzarfati1

1AMHC, Bat Yam, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Israel
2KIOR, Almaty, affiliated to the National Medical University, RK
3WMC, Holon, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Israel

Submission: July 30, 2017; Published: August 08, 2017

*Corresponding author: Gimelfarb Yuri, AMHC, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Bat Yam 5943602, Israel, Tel: +972 35552749; Email: Ystatist@gmail.com

Abstract

Background: Little is known about the impact of integrated dual disorders service (based on social health insurance) utilization by population of dual diagnosis (severe mental illness and co-occurring substance use disorders), in the early stages of illness, on long-term survival.

Objective: To determine the benefit of integrated dual disorders services utilization on long-term survival of these patients in the early stages of schizophrenia and co-occurring substance use disorders.

Methods: The medical records of patients admitted to the Integrated Dual Disorders Treatment Ward (IDDTW) from January 1, 2002 to December 31, 2006 were assessed. Psychiatric diagnoses had been established according to the International Classification of Diseases and Health related Problems-10th edition. The Kaplan-Meier Survival Analysis was used to estimate the cumulative survival rates in all the subpopulations, and the risk of all-cause mortality was assessed by Cox proportional-hazards regression models, with and without time-dependent covariates.

Results: During the 10.8-year median follow-up of 275 patients (of them 239 (86.9%) males), 63 (22.9%) patients died. In a time-dependent adjusted regression models, more than one year of cumulative length of stay (HR=2.48; 95% CI 1.42 to 4.34; p<.0001) and more than 2 admissions (HR=1.90; 95% CI 1.02 to 3.54; p<.001) in standard psychiatric inpatient services before the 1st admission in integrated dual disorders treatment ward were significant predictors of higher all-cause mortality.

Conclusion: In order to facilitate accessible and available care, and to increase the long-term survival rates for these patients, the development and expansion of licensed integrated dual disorders inpatient services is recommended.

Keywords: Service utilization; Integrated dual disorders services; Benefit; all-cause mortality; Long-term follow-up; Kaplan-Meier survival analysis; Cox proportional-hazard regression model


Introduction

First-episode schizophrenia-related psychosis and co-occurring substance use disorders

The research on first-episode psychosis emphasizes the importance of early and appropriate interventions to initiate remissions and to prevent relapses [1-3]. The literature on first-episode psychosis highlights the high prevalence and adverse consequences of substance use, misuse, or disorder [4,5]. Significant proportions of patients have use disorders related to alcohol [4,6], cannabis [4-7], cocaine, amphetamines, barbiturates, and other drugs [2,4,5,7]. Overall, approximately half of all clients with first episodes of psychosis present for treatment with a current substance use disorder.
Schizophrenia with co-occurring substance use disorders is associated with multiple adverse outcomes, including treatment non-adherence [2], recurrent admissions[4,6], violence [8], relapse [6] and suicide attempts [9], as well as medical problems such as HIV and viral hepatitis [10,11], and increased all-cause mortality [12,13]. The course of substance use disorders in this population tends to be chronic and relapsing [14,15]. Traditional parallel treatment approaches (in separate settings) have been established as being ineffective and fragmented, and result in treatment non-adherence and dropout [16,17].

Integrated dual disorders services

The negative outcomes associated with traditional approaches in the treatment of dual disorders led in the 1980s to integrated treatments designed to target co-occurring mental and substance use disorders concurrently in the same setting \[18,19\]. Several reviews of experimental and quasi-experimental studies support different types of integrated treatment, including group counseling, contingency management, residential treatment, and motivational interventions combined with cognitive-behavioral treatment \[17,20\].

The 1994 National Health Insurance Law stated that healthcare in Israel would be “based on the principle of justice, equality and mutual assistance”.

Unfortunately, in the area of mental healthcare, the treatment of substance use disorders has been characterized by neglect; the budget is minimal and treatment has been focused primarily on drug detoxification programs \[21\]. This can be seen clearly in the area of integrated treatment of comorbid mental and substance use disorders where the number of offered treatments has been very restricted; only 2 open wards for inpatient treatment in government mental health centers and 20 community care beds. As a result, patients with dual diagnoses have been forced to be hospitalized in standard psychiatric inpatient services; in mental health centers or general hospitals \[22,23\].

Integrated inpatient care has not been found to be better than mixed care (life-time integrated dual disorders inpatient services and standard psychiatric wards) in the prevention of long-term all-cause mortality \[13\]. Nevertheless, little is known about the long term survival rates in patients with schizophrenia and co-occurring substance use disorders in the early stages: with and without admissions in integrated dual disorders services. The objective of this study was to determine the benefit of integrated dual disorders services utilization in the early stages of schizophrenia and co-occurring substance use disorders on these patients’ long-term survival.

Materials and Methods

Study design

This was a retrospective analysis of prospectively collected data. This study was approved by the Institutional Review Board and conducted according to the World Medical Association Declaration of Helsinki -ethical principles for medical research involving human subjects.

Study participants

To participate in the study patients had to meet the followed inclusion criteria:

a) Age: 18-65 years old;

b) Both genders;

c) be members of any one of the health funds in Israel: Clalit, Maccabi, Leumit and Meuchedet;

d) Admitted at least once to the Integrated Dual Disorders Treatment Ward (IDDTW) in our center between January 1, 2002 (opening of the IDDTW) and December 31, 2006;

e) With or without lifetime admissions to the other inpatient services within our center or other facilities;

f) Schizophrenia spectrum disorders (F20-F25) according to the International Classification of Diseases and Health related problems-10th edition (ICD-10);

f) Substance dependence/addiction according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revised (DSM-IV-TR);

h) All types of admissions (voluntary, forced, mixed);

i) With or without Methadone or Buprenorphine or Buprenorphine/Naloxone (detoxification or maintenance) treatment;

j) With or without any type of psychopharmacological treatment.

Exclusion criteria were:

a) The absence of Israeli citizenship during the admission (tourists, refugees, work seekers);

b) Patients admitted during the study period only for general psychiatric examination requested by authority (with or without lifetime admissions to the other psychiatric facilities).

Details of the study design have been described elsewhere [12,13]. All the subsequent patients meeting the study criteria were assessed.

Assessments

The clinical data, including the date of the first admission to the IDDTW, was obtained from “Prometheus - clinical charts”, 14.3th version”. All the patients were clinically monitored as part of the clinical process during the admission. The data on death dates were obtained from the information data base of the admission, discharge and transfer (ATD) program. The date of the first admission at the IDDTW was the date of the beginning of the follow-up in this study. Census date of survival was on July
Demographics and clinical characteristics of patient population (N=275).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, males - n (%)</td>
<td>239 (86.9)</td>
</tr>
<tr>
<td>Age at entry, median years (IQR)</td>
<td>33.2 (26.0-40.9)</td>
</tr>
<tr>
<td>Sickness fund, n (%)</td>
<td></td>
</tr>
<tr>
<td>Clalit</td>
<td>151 (54.9)</td>
</tr>
<tr>
<td>Maccabi</td>
<td>75 (27.5)</td>
</tr>
<tr>
<td>Leumit</td>
<td>28 (10.2)</td>
</tr>
<tr>
<td>Meuchedet</td>
<td>21 (7.6)</td>
</tr>
<tr>
<td>Length of stay (LOS) before IDDTW, median years (IQR)</td>
<td>0.4 (0.04-1.6)</td>
</tr>
<tr>
<td>Number of previous admissions in standard psychiatric wards before IDDTW, median number (IQR)</td>
<td>4.0 (1.0-8.0)</td>
</tr>
</tbody>
</table>

Outcome measure


Statistical analysis

Data were analyzed using the Statistical Package for Social Sciences version 20.0 for Windows (SPSS, An IBM Company, version 20). Categorical variables have been presented by frequency tables (numbers with percentages). Continuous variables have been presented by median with range and inter-quartile range (IQR). The survival analysis was performed by the Kaplan-Meier method (using Log Rank test). The Cox proportional-hazard models with Hazard Risk (HR) and 95% Confidence Interval (95% CI) were used to assess the risk of all-cause mortality, with and without time-dependent covariates. P-values less than 0.05 were considered to be statistically significant.

Results

Study population

The study population consisted of 275 patients who met the inclusion / exclusion criteria (Table 1). The median age of patients was 33.2 years (range 18.7 - 64.6 years) at the beginning of the follow-up, of them 239 (86.9%) were males. The majority of patients (54.9%) were insured by the Clalit health fund. Median observation time was 10.8 years (range .06 - 13.5 years; IQR 8.9 - 12.4 years). Out of patient population 63 (22.9%) patients died. The median length of stay in standard psychiatric inpatient services before the first admission in IDDTW was 0.4 years (range 0.0 - 30.7 years). The number of previous admissions (as continuous variable) in standard psychiatric inpatient services before the 1\textsuperscript{st} admission in IDDTW was redefined into dichotomy variables: yes vs. no, more than one admission vs. others, more than 2 admissions vs. others, more than 3 admissions vs.. others, more than 4 admissions vs. others (Table 2).

Table 1: Demographics and clinical characteristics of patient population (N=275).

Forty five patients (16.4%) had lifetime admissions in integrated dual disorders services only. The discharge of the last of them was at May1, 2008. The most frequent main psychiatric diagnosis was schizophrenia (n=220; 80.0%). Seventy four patients (26.9%) had Dissocial personality disorder of all the patients, 15 (5.5%) presented with hepatitis B virus and hepatitis C virus (HBV/HCV) co-infection. Four patients (1.5%) had human immunodeficiency virus / acquired immunodeficiency syndrome. One hundred and forty seven patients (53.5%) had lifetime positive results for psychoactive substances in urine analysis. Out of them, 87 patients (59.1%) had positive results for more than one substance.

Admissions in standard psychiatric inpatient services before the 1\textsuperscript{st} admission in IDDTW and long-term survival

The number of previous admissions (as continuous variable) in standard psychiatric inpatient services before the 1\textsuperscript{st} admission in IDDTW has not been found to be predictive of long-term survival, neither in time-independent (NS) nor in time-dependent unadjusted models (NS). The variable admissions in standard psychiatric inpatient services before the 1st admission in IDDTW was redefined into dichotomy variables: yes vs. no, more than 1 admission vs. others, more than 2 admissions vs. others, more than 3 admissions vs.. others, more than 4 admissions vs. others (Table 2).

From the data presented in Table 2, it can be seen that the strongest prediction of long-term survival has been detected by the dichotomy variable “more than 2 admissions vs. others”: in time-independent (HR=1.98; 95% CI 1.14 to 3.46; p<.001), time-dependent unadjusted (HR=1.98; 95% CI 1.14 to 3.46; p<.001) and time-dependent adjusted models (HR=1.90; 95% CI 1.02 to 3.54; p<.001). It was the only variable that...
significantly associated with all-cause mortality in all of the models, mentioned above. For patients, that had more than 2 admissions in standard psychiatric inpatient services before the 1st admission in IDDTW the hazard ratio was 1.90 times higher (95% CI 1.02 to 3.54; p<.001) than for patients with 2 and fewer admissions in standard psychiatric inpatient services before the 1st admission in IDDTW, in the time-dependent adjusted model.

**Table 2**: Relative risk, by admissions before the 1st admission in IDDTW (N=275), HR (95% CI).

<table>
<thead>
<tr>
<th>Admissions before IDDTW</th>
<th>Time-independent (unadjusted)</th>
<th>Time-dependent (unadjusted)</th>
<th>Time-dependent (adjusted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (n=216) vs no (n=59)</td>
<td>1.10 (.59-2.07)</td>
<td>1.10 (.59-2.07)</td>
<td>.94 (.45-1.94)</td>
</tr>
<tr>
<td>&gt;1 admission (n=180) vs others (n=95)</td>
<td>1.55 (.88-2.74)</td>
<td>1.55 (.88-2.74)</td>
<td>1.46 (.78-2.74)</td>
</tr>
<tr>
<td>&gt;2 admissions (n=161) vs others (n=114)</td>
<td><strong>1.98 (1.14-3.46)</strong></td>
<td><strong>1.98 (1.14-3.46)</strong></td>
<td><strong>1.90 (1.02-3.54)</strong></td>
</tr>
<tr>
<td>&gt;3 admissions (n=142) vs others (n=133)</td>
<td>*1.66 (.99-2.77)</td>
<td>*1.66 (.99-2.77)</td>
<td>*1.48 (.84-2.61)</td>
</tr>
<tr>
<td>&gt;4 admissions (n=121) vs others (n=154)</td>
<td>1.42 (.87-2.34)</td>
<td>1.42 (.87-2.34)</td>
<td>1.22 (.72-2.08)</td>
</tr>
</tbody>
</table>

*p<.05
** p<.01
*** p<.001

Adjusted for gender, age at entry, sickness fund, type of life-time care, Dissocial personality disorder, viral hepatitis and HIV.

**Length of stay (LOS) before the 1st admission in IDDTW and long-term survival**

LOS (as continuous variable) before the 1st admission in IDDTW has not been found to be predictive of the long-term survival, neither in time-independent (NS) nor in time-dependent unadjusted models (NS). The variable LOS before admission in IDDTW was redefined into dichotomy variables: yes vs. no, LOS more than 0.5 year vs. others, LOS more than 1 year vs. others, LOS more than 2 years vs. others, LOS more than 3 years vs. others (Table 3).

From the data presented in Table 3, it can be seen that the strongest prediction of long-term survival has been detected by the dichotomy variable “LOS more than 1 year vs. others”: in time-independent (HR=2.46; 95% CI 1.50 to 4.04; p<.0001), time-dependent unadjusted (HR=2.48; 95% CI 1.51 to 4.06; p<.0001) and time-dependent adjusted models (HR=2.48; 95% CI 1.42 to 4.34; p<.0001). It was the only variable which has statistically significant association with all-cause mortality in all of the models, mentioned above. For patients, that have LOS more than one year before admissions in IDDTW the hazard ratio was 2.48 times higher (95% CI 1.42 to 4.34; p<.0001) than for patients with LOS of one year or less before admissions in IDDTW, in time-dependent adjusted model.

**Table 3**: Relative risk, by LOS before the 1st admission in IDDTW (N=275), HR (95% CI).

<table>
<thead>
<tr>
<th>LOS</th>
<th>Time-independent (unadjusted)</th>
<th>Time-dependent (unadjusted)</th>
<th>Time-dependent (adjusted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes (n=229) vs no (n=46)</td>
<td>.88 (.46-1.68)</td>
<td>.88 (.46-1.69)</td>
<td>.75 (.34-1.64)</td>
</tr>
<tr>
<td>&gt;0.5 year (n=130) vs others (n=145)</td>
<td>^1.62 (.98-2.67)</td>
<td>^1.62 (.98-2.67)</td>
<td>*1.76 (1.00-3.09)</td>
</tr>
<tr>
<td>&gt;1 year (n=82) vs others (n=193)</td>
<td>***2.46 (1.50-4.04)</td>
<td>***2.48 (1.51-4.06)</td>
<td>***2.48 (1.42-4.34)</td>
</tr>
<tr>
<td>&gt;2 years (n=52) vs others (n=223)</td>
<td>*1.85 (1.08-3.17)</td>
<td>*1.86 (1.08-3.18)</td>
<td>*1.92 (1.02-3.60)</td>
</tr>
<tr>
<td>&gt;3 years (n=36) vs others (n=239)</td>
<td>1.71 (.93-3.14)</td>
<td>1.71 (.93-3.15)</td>
<td>1.58 (.77-3.23)</td>
</tr>
</tbody>
</table>

*p<.05
** p<.01
*** p<.001
^ p<.06

Adjusted for gender, age at entry, sickness fund, type of life-time care, Dissocial personality disorder, viral hepatitis and HIV.

Survival rates of subjects who were hospitalized for up to, or more than, one year, in standard psychiatric inpatient services, at various follow-ups, can be seen in Table 4. From this table, it can be seen that survival rates at 5, 10 and 12 years in population with more than one year of hospitalization was 85.4%, 67% and 54% respectively. The survival rate of those subjects who had been hospitalized for up to one year, at 5, 10 and 12 year follow-up, was 90.2%, 83.7% and 82.8% respectively. There was a statistically significant difference in the survival rates between the two sub populations (X2 of Log Rank = 13.7; df=1, p<.0001) see Figure 1.

**Table 4**: Survival time, according to LOS before admission in IDDTW (N=275).

<table>
<thead>
<tr>
<th>LOS</th>
<th>Survival rates, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1-year</td>
</tr>
<tr>
<td>&lt; 1 year (n=193)</td>
<td>97.4</td>
</tr>
<tr>
<td>&gt; 1 year (n=82)</td>
<td>95.2</td>
</tr>
</tbody>
</table>

Survival rates computed using the Kaplan-Meier method

X2 of Log Rank = 13.7; df = 1; p < .0001.
Discussion

The current study focused on the benefit of integrated dual disorders service utilization in the prevention of all-cause mortality among schizophrenic patients who also suffered from comorbid substance use early in their illness. This was assessed by means of follow up for more than 10 years, before the initiation of the largest reform in mental health services ever in Israel [29]. One of the main findings in this study was that those schizophrenic patients who had NOT used the integrated dual disorders inpatient services for their comorbid disorders during the first two hospitalizations for their illness had a 90% higher risk of mortality than those patients who DID use them. Another central finding from our study was that schizophrenic comorbid patients who did NOT use the integrated dual disorders inpatient services during the first cumulative year of hospitalizations had a 148% higher risk of mortality than those DID use them.

To the best of our knowledge, there is no other scientific evidence of the benefit of early integrated treatment of comorbid schizophrenia and substance use disorders in the prevention of all-cause mortality in this population of patients with unique treatment requirements. Among the reasons for the association of this kind of treatment with lower mortality at follow up, one may be able to discern the following factors. First, during integrated treatment the patient is exposed early in their illness to a variety of treatments that, together, can prevent all-cause mortality at follow-up: 12-step program, motivational interviewing, the adoption of healthy behavior patterns, the elimination of harmful health habits, appropriate pharmacological treatments (both for the mental illness and the substance use disorders), e.g. drug rehabilitation and drug toxicity treatment [17,18,29-31].

Second, transfer to a personally tailored treatment facility for continued treatment after hospitalization, and NOT to a standard psychiatric treatment framework, e.g. a therapeutic community facility; maintenance outpatient treatment for drug substitute treatment (e.g. Methadone or Buprenorphine or Buprenorphine/Naloxone); a residence hostel for those suffering from dual diagnosis; a community clinic for dual diagnosis patients; day treatment for dual diagnosis [29] third a longer period of hospitalization in a dual diagnosis inpatient unit than in a general psychiatric unit. This can lead to increased compliance, longer exposure to a variety of treatments than is available in a standard psychiatric service [18,30,31].

It should be noted that the sub-population that was studied in the present research was hospitalized in standard psychiatric departments not only before special dual diagnosis services began to open, but also after they were opened, and for a number of years after that. It cannot be excluded that this happened because of a lack of awareness among the treatment staff in the standard psychiatric departments that there was a dual diagnosis diagnostic entity. That said, the main reason for this phenomenon lies in the acute shortage of hospital beds available for the target patient population. As a result, patients with comorbid disorders were required to resign themselves

Figure 1: The probability of survival according to LOS before admission in IDDTW (N=275).
to hospitalization in standard psychiatric inpatient services [22,23].

It is important, in discussing the findings from this study, that we do not ignore the following issues first, hospitalizations of dual diagnosis patients in standard child and adolescent psychiatric units. Until now there have been no treatment services for adolescents presenting with comorbid psychiatric and substance use disorders. It is possible that the time has come to plan, establish and check the efficacy of integrated dual disorders inpatient services for this population. Second, the lack of dedicated services in the community for those with comorbid disorders during most of the period of the study [29]. This may have been an additional factor in the re-hospitalization of some of those with dual diagnosis, and not always in an integrated dual disorders inpatient service.

Third, it is recommended that the establishment of additional licensed treatment units offering integrative treatment to those with comorbid disorders be seriously considered. During the time that this study was being conducted there were no significant changes in the number and quality of such services being provided in Israel. There is no doubt that the development of additional services, and the expansion of existing ones, will require appropriate funding that will enable suitable staffing, equipment, therapeutic interventions, etc. Excess mortality among patients with severe mental disorders presents a challenge to both clinicians and policy makers [28].

In the spirit of the policy of the World Health Organization (WHO), our series of research studies is designed to identify possible risk factors contributing to excess mortality among dually diagnosed mentally ill patients - after long-term follow-up. Our previous studies [12,13] illustrated the importance of the seriousness of the phenomenon of excess mortality in this patient subgroup. In the current study, an additional sub-population has been identified; those with comorbid schizophrenia and substance use disorders who were not treated in an integrated dual disorders inpatient service for their health issues in the early stages of their illness, but, rather, in standard psychiatric services.

Limitations of the study

One of the limitations is that the actual causes of the cases of mortality are not identified. Also, other variables were not studies, e.g. quality of life, vocational rehabilitation, social integration, prevention of hospitalizations, and others. In addition, over a period of 10 years or more, there may have been changes in the conceptualization of treatment for this population of patients; in the context of the beginning of use of drug substitutes, medical substances etc.

Conclusion

In order to facilitate accessible and available treatment for patients with comorbid psychiatric and substance use disorders, and to increase their rate of long term survival, it is recommended that licensed integrated dual disorders inpatient services be developed and expanded for this patient group with unique treatment needs. The efforts of the Ministry of Health and of the sickness funds to appropriate the integrated dual disorders services to the unique demands of this population should be evaluated again after implementation of the largest mental health care reform in Israel, that has been took place in July 2015.

Acknowledgement

Ruti Cohen-Zemach - for the help in data collection.

Conflict of interest

The authors declare that they have no competing interests.

*Note: Presented in part at the 12th Annual Health Policy Conference (2017, May) of the Israel National Institute for Health Policy Research (NIHP), Tel Aviv, Israel and at the annual congress of Israeli Association of Public Health Physicians (2017, June), Tel Aviv, Israel.

References

11. Gimelfarb Y, Ben Tzarfati M (2017) Impact of hepatitis B (HBV)/C (HCV) virus co-infection on the survival of schizophrenic patients with...
co-occurring substance use disorders followed for 12 years. European Psychiatry 41:5862-5863.


Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php